Daily Newsletter

23 August 2023

Daily Newsletter

23 August 2023

Regeneron partners with US Government to develop Covid-19 antibody vaccine

The programme is part of US BARDA’s ‘Project NextGen’ to develop countermeasures against Covid-19 current and future strains.

Phalguni Deswal August 23 2023

US-based Biomedical Advanced Research and Development Authority (BARDA) has partnered with Regeneron on the Covid-19 monoclonal antibody vaccine clinical development programme.

A part of the US Government’s Strategic Preparedness and Response division, BARDA has entered the partnership as part of Project NextGen. The project plans to leverage public-private partnerships to develop vaccines and therapies for Covid-19 SARS-CoV-2 and other future strains.

There has been an increased demand for Covid-19 vaccines that target the new variants, specifically Omicron, after the European Medicines Agency’s (EMA) decision to seek SARS-CoV-2 XBB 1.5 Omicron subvariant Covid-19 vaccines.

As per the current agreement, Regeneron will independently invent an antibody candidate for Covid-19. Following this, both parties will evaluate the further development of the candidate. BARDA will then fund up to $326m for the vaccine development.

In a press release, Regeneron CEO Leonard S Schleifer said: “Although Covid-19 has moved to an endemic stage, many people – including those with immunocompromising conditions – continue to face exposure that impacts their everyday life and could cause serious health consequences.

“American biopharmaceutical companies developed remarkable Covid-19 therapeutics and vaccines in record time, successfully changing the course of the pandemic, and we’re gratified that the US Government continues to support early research from this uniquely innovative industry.”

The current partnership expands on the previous $450m agreement between BARDA and Regeneron to supply the Covid-19 vaccine.

BARDA also has a collaboration agreement with Regeneron to develop a portfolio of antibodies to target ten public-risk-causing pathogens, including influenza. Recently, BARDA ordered smallpox and mpox vaccines from Bavarian Nordic as part of its preparedness response.

Multiple Myeloma (MM) pipeline is dominated by CAR-T cells

The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline, with these therapies having an “off-the-shelf” advantage over autologous therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close